Indian listed arm of P&G selling feminine hygiene (Whisper) and healthcare products (Vicks) in India.
Indian listed arm of P&G selling feminine hygiene (Whisper) and healthcare products (Vicks) in India.
Sells branded goods through distributors and pharmacies. Feminine hygiene is a year-round staple, while Vicks remedies peak in the winter and monsoon months. The brands and know-how come from the US group Procter & Gamble, which controls the company.
Moat: narrow (brand, distribution). Leading, trusted brands (Whisper, Vicks) with deep retail and pharmacy distribution across India.
Headquarters: Mumbai, India · Founded: 1964 · Employees: 712
Size Procter & Gamble Hygiene & Health Care (PGHH.NS) is an India Consumer Staples company (Household/Personal Care) with a market value of $2.37B, the 342nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹6,829 on 18 Nov 2026.
Performance Over six months the shares fell 29.6%, against +0.3% for the median peer and +3.8% for the India market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 2.0% over the last twelve months (peer median +3.3%); the operating margin is 23.8% (peer median 10.6%).
Valuation It trades at 27.0× forward earnings against a peer median of 21.5× (8th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹42.4B | ₹42.9B | ₹45.0B | ₹39.2B | ₹39.0B |
| Revenue growth | — | -5% | +15% | 0% | — |
| Gross profit | ₹23.4B | ₹22.3B | ₹23.2B | ₹17.3B | ₹17.2B |
| EBITDA | ₹10.5B | ₹12.0B | ₹11.9B | ₹8.74B | ₹8.39B |
| Net income | ₹7.77B | ₹8.56B | ₹8.49B | ₹6.78B | ₹5.76B |
| Free cash flow | n/a | ₹9.13B | ₹5.67B | ₹8.11B | ₹5.44B |
| Capital expenditure | n/a | ₹495M | ₹550M | ₹444M | ₹498M |
| Total debt | ₹3.30M | ₹8.70M | ₹23.2M | ₹40.3M | ₹51.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Procter & Gamble Hygiene & Health Care PGHH.NS | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% |
| Hindustan Unilever HINDUNILVR.NS | $50.0B | -11% | +6% | 21% | 41.4× | 27.4% |
| Emami EMAMILTD.NS | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% |
| Dabur India DABUR.NS | $7.16B | -16% | +9% | 15% | 31.8× | 27.4% |
| Reckitt Benckiser RKT.L | $47.5B | +22% | -2% | 28% | 16.7× | 2.1% |
| Kenvue KVUE | n/a | +12% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PGHH.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | +2.2% | 8th lowest of 21 |
| 6-month return | -29.6% | +0.3% | 3rd lowest of 21 |
| Distance from 52-week high | -48.1% | -24.0% | 2nd lowest of 21 |
| Revenue growth (TTM) | -2.0% | +3.3% | 6th lowest of 21 |
| Operating margin | 23.8% | 10.6% | 4th highest of 21 |
| Forward P/E | 27.0× | 21.5× | 8th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 21.2% | -1.8% | 2nd most demanding of 17 |
| Growth delivered (Del g) | +7.4% | +3.8% | 8th highest of 17 |
| Hurdle (Req g minus delivered) | +13.8 pp | -4.1 pp | 4th most demanding of 17 |
| EV / EBITDA | 20.4× | 11.3× | 3rd most expensive of 15 |
| Net debt / EBITDA | -0.7× | -1.5× | 8th most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% | -4.1% |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% | +23.1% |
| Emami EMAMILTD.NS | India | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% | +5.6% |
| Energizer ENR | United States | $1.94B | +71% | 0% | 17% | 9.1× | -5.1% | -0.5% |
| Pigeon 7956.T | Japan | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% | +1.9% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% | +1.9% |
| Hengan Int'l 1044.HK | Hong Kong | $3.27B | -12% | +2% | 11% | 9.1× | -8.2% | -0.1% |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |
| Interparfums ITP.PA | France | $3.49B | +66% | -4% | 18% | 26.9× | 15.6% | +19.6% |
| Shanghai Jahwa United 600315.SS | China | $1.61B | -15% | +9% | 2% | 15.4× | 15.3% | -2.1% |